Scynexis Inc financial data

Symbol
SCYX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1 Evertrust Plaza, 13 Th Floor, Jersey City, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 498 % +20.4%
Quick Ratio 25.8 % +354%
Debt-to-equity 68 % -83.4%
Return On Equity -47.3 % -122%
Return On Assets -28.1 % -167%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 37.9M shares +1.83%
Common Stock, Shares, Outstanding 37.9M shares +1.83%
Entity Public Float 60.2M USD -64.4%
Weighted Average Number of Shares Outstanding, Basic 48.5M shares +1.41%
Weighted Average Number of Shares Outstanding, Diluted 48.5M shares -2.83%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 736K USD
Research and Development Expense 31.1M USD +9.92%
Operating Income (Loss) -51.9M USD -184%
Nonoperating Income (Expense) 17.2M USD -191%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -34.7M USD -178%
Income Tax Expense (Benefit) 669K USD
Net Income (Loss) Attributable to Parent -35.4M USD -180%
Earnings Per Share, Basic -0.74 USD/shares -186%
Earnings Per Share, Diluted -0.65 USD/shares -184%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 26M USD -55.1%
Cash, Cash Equivalents, and Short-term Investments 83.7M USD -8.92%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Inventory, Net 0 USD -100%
Other Assets, Current 554K USD -50.1%
Assets, Current 94.6M USD -35%
Property, Plant and Equipment, Net 61K USD -77.5%
Operating Lease, Right-of-Use Asset 2.23M USD -10.1%
Intangible Assets, Net (Excluding Goodwill) 0 USD -100%
Other Assets, Noncurrent 0 USD -100%
Assets 108M USD -30.4%
Accounts Payable, Current 5.35M USD +56.6%
Accrued Liabilities, Current 5.5M USD -23.5%
Liabilities, Current 25.2M USD +56.2%
Operating Lease, Liability, Noncurrent 2.39M USD -13.5%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 47.4M USD -23.3%
Retained Earnings (Accumulated Deficit) -369M USD -10.6%
Stockholders' Equity Attributable to Parent 60.4M USD -35.1%
Liabilities and Equity 108M USD -30.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.01M USD +78.8%
Net Cash Provided by (Used in) Financing Activities 22K USD -99.7%
Net Cash Provided by (Used in) Investing Activities 5.45M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 37.9M shares +1.83%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26.5M USD -54.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 420K USD -74.7%
Deferred Tax Assets, Valuation Allowance 60.6M USD -41.4%
Deferred Tax Assets, Gross 60.6M USD -41.4%
Operating Lease, Liability 2.76M USD -10.1%
Lessee, Operating Lease, Liability, to be Paid 3.9M USD -15.6%
Operating Lease, Liability, Current 372K USD +20%
Lessee, Operating Lease, Liability, to be Paid, Year Two 759K USD +2.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 744K USD +1.92%
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.14M USD -26.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 774K USD +1.98%
Deferred Tax Assets, Operating Loss Carryforwards 46.4M USD -47.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 361K USD -17.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 790K USD +2.07%
Operating Lease, Payments 723K USD +11.4%
Additional Paid in Capital 430M USD +0.64%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 2.65M USD -9.3%
Interest Expense 836K USD -85.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%